Pre-admission antibiotics for suspected cases of meningococcal disease

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2017, Pages

  Sudarsanam, Thambu D ^a   Rupali, Priscilla ^a   Tharyan, Prathap ^a   Abraham, Ooriapadickal Cherian ^a   Thomas, Kurien ^b  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b OMAN MEDICAL SPECIALTY BOARD   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; CHLORAMPHENICOL; PLACEBO; ANTIINFECTIVE AGENT;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL OUTCOME; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ECONOMIC ASPECT; EPIDEMIC; EVIDENCE BASED MEDICINE; HOSPITAL ADMISSION; HUMAN; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; NEUROLOGICAL COMPLICATION; NIGER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; ANTIBIOTIC PROPHYLAXIS; COMPLICATION; INTRAMUSCULAR DRUG ADMINISTRATION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CEFTRIAXONE; CHLORAMPHENICOL; HUMANS; INJECTIONS, INTRAMUSCULAR; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; PATIENT ADMISSION;

EID: 85020711439     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005437.pub4     Document Type: Review

References (92)

1. Nathan N, Borel T, Djibo A, Evans D, Djibo S, Corty JF, et al. Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study. Lancet 2005;366:308-13. 2691760
2. Barquet N, Domingo P, Cayla JA, Gonzalez J, Rodrigo C, Fernandez-Viladrich P, et al. Prognostic factors in meningococcal disease: Development of a bedside predictive model and scoring system. JAMA 1997;278(6):491-6. 2691762
3. Barquet N, Domingo P, Cayla JA, Gonzalez J, Rodrigo C, Fernandez-Viladrich P, et al. Meningococcal disease in a large urban population (Barcelona, 1987-1992): predictors of dismal prognosis. Archives of Internal Medicine 1999;159(19):2329-40. 2691764
4. Barson WJ, Miller MA, Brady MT, Powell DA. Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children. Pediatric Infectious Disease 1985;4(4):362-8. [CN-00039069]2691766
5. Bohr V, Rasmussen N, Hansen B, Kjersem H, Jessen O, Johnsen N, et al. 875 cases of bacterial meningitis: diagnostic procedures and the impact of preadmission antibiotic therapy. Part III of a three-part series. Journal of Infection 1983;7(3):93-202. 2691768
6. BSSI Research Committee. Bacterial meningitis: causes for concern. Journal of Infection 1995;30(2):89-94. [7478351]2691770
7. Cartwright K, Reilly S, White D, Stuart J. Early treatment with parenteral penicillin in meningococcal disease. BMJ 1992;305(6846):143-7. 2691772
8. Congeni BL. Comparison of ceftriaxone and traditional therapy of bacterial meningitis. Antimicrobial Agents & Chemotherapy 1984;25(1):40-4. [CN-00033949]2691774
9. del Rio MA, Chrane D, Shelton S, McCracken GH Jr, Nelson JD. Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children. Lancet 1983;321(8336):1241-4. [CN-00031211]2691776
10. Gedde-Dahl TW, Hoiby EA, Brandtzaeg P, Eskerud JR, Bovre K. Some arguments on early hospital admission and treatment of suspected meningococcal disease cases. NIPH Annals 1990;13(2):45-60. 2691778
11. Girgis NI, Farid Z, Mikhail IA, Farrag I, Sultan Y, Kilpatrick ME. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatric Infectious Disease Journal 1989;8(12):848-51. [CN-00066058]2691780
12. Gunn A, Hollyoak V. Meningitis: public health issues. Nursing Times 1996;92(6):27-9. 2691782
13. Harnden A, Ninis N, Thompson M, Perera R, Levin M, Mant D, et al. Parenteral penicillin for children with meningococcal disease before hospital admission: case-control study. BMJ 2006;332(7553):1295-8. [DOI: 10.1136/bmj.38789.723611.55]2691784
14. Jolly K, Stewart G. Epidemiology and diagnosis of meningitis: results of a five-year prospective, population-based study. Communicable Disease and Public Health 2001;4(2):124-9. 2691786
15. Kavaliotis J, Manios SG, Kansouzidou A, Danielidis V. Treatment of childhood bacterial meningitis with ceftriaxone once daily: open, prospective, randomized, comparative study of short-course versus standard-length therapy. Chemotherapy 1989;35(4):296-303. [CN-00061937]2691788
16. Leclerc F, Noizet O, Dorkenoo A, Cremer R, Leteurtre S, Sadik A, et al. Treatment of meningococcal purpura fulminans. Archives de Pediatrie 2001;8(Suppl 4):667-88. [MEDLINE: 2001324586]2691790
17. Martin E, Hohl P, Guggi T, Kayser FH, Fernex M. Short course single daily ceftriaxone monotherapy for acute bacterial meningitis in children: results of a Swiss multicenter study. Part I: clinical results. Infection 1990;18(2):70-7. [CN-00067277]2691792
18. Molyneux E, Nizami SQ, Saha S, Huu KT, Azam M, Bhutta ZA, et al. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet 2011;377(9780):1837-45. 2691794
19. Newcombe J, Dyer S, Blackman L, Cartwright K, Palmer WH, McFadden J. PCR-single-stranded confirmational polymorphism analysis for non-culture-based subtyping of meningococcal strains in clinical specimens. Journal of Clinical Microbiology 1997;35(7):1809-12. 2691796
20. Noorgard B, Soorensen HT, Jensen ES, Faber T, Schoonheyder HC, Nielsen GL. Pre-hospital parenteral antibiotic treatment of meningococcal disease and case fatality: a Danish population-based cohort study. Journal of Infection 2002;45(3):144-51. 2691798
21. Pecoul B, Varaine F, Keita M, Soga G, Djibo A, Soula G, et al. Long-acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis. Lancet 1991;338(8771):862-6. [CN-00078644]2691800
22. Perea-Milla E, Olalla J, Sanchez-Cantalejo E, Martos F, Matute-Cruz P, Carmona-Lopez G, et al. Pre-hospital antibiotic treatment and mortality caused by invasive meningococcal disease, adjusting for indication bias. BMC Public Health 2009;9:95. [Research Support, Non-U.S. Gov't 19344518]2691802
23. Quagliarello V. Short-course penicillin therapy for meningococcal disease: accumulating evidence and persistent uncertainty. Clinical Infectious Diseases 2003;37(5):663-4. [MEDLINE: 2003369547]2691804
24. Riordan FAI. Improving promptness of antibiotic treatment in meningococcal disease. Emergency Medicine Journal 2001;18(3):162-3. [MEDLINE: 2002028693]2691806
25. Rodriguez WJ, Puig JR, Khan WN, Feris J, Gold BG, Sturla C. Ceftazidime vs. standard therapy for pediatric meningitis: therapeutic, pharmacologic and epidemiologic observations. Pediatric Infectious Disease 1986;5(4):408-15. [CN-00043513]2691808
26. Roord JJ, Kaandorp CJ. CBO-guideline 'Bacterial meningitis'. Nederlands Tijdschrift voor Geneeskunde 2001;145(5):211-4. 2691810
27. Roznovsky L, Krizova P, Struncova V, Dostal V, Plisek S, Kasal E, et al. Administration of antibiotics before admission in patients with meningococcal disease. Central European Journal of Public Health 2003;11(1):14-8. 2691812
28. Schaad UB, Suter S, Gianella-Borradori A, Pfenninger J, Auckenthaler R, Bernath O, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. New England Journal of Medicine 1990;322(3):141-7. [CN-00064505]2691814
29. Sorensen HT, Nielsen GL, Schonheyder HC, Steffensen FH, Hansen I, Sabroe S, et al. Outcome of pre-hospital antibiotic treatment of meningococcal disease. Journal of Clinical Epidemiology 1998;51(9):717-21. [MEDLINE: 1998321631]2691816
30. Strang JR, Pugh EJ. Meningococcal infections: reducing the case fatality rate by giving penicillin before admission to hospital. BMJ 1992;305(6846):141-3. 2691818
31. Wald ER, Kaplan SL, Mason EOJ, Sabo D, Ross L, Arditi M, et al. Dexamethasone therapy for children with bacterial meningitis. Pediatrics 1995;95(1):21-31. [CN-00174080]2691820
32. Wylie PAL, Stevens D, Drake W 3rd, Stuart J, Cartwright K. Epidemiology and clinical management of meningococcal disease in west Gloucestershire: retrospective, population based study. BMJ 1997;315(7111):774-9. [MEDLINE: 1997291389]2691822
33. Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. Journal of Travel Medicine 2010;17:3-8.
34. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
35. Baraff LJ. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatric Infectious Disease Journal 1993;12:389-94.
36. Belo EFT, Farhat CK, Gaspari END. Comparison of dot-ELISA and standard ELISA for detection of Neisseria meningitidis outer membrane complex-specific antibodies. Brazilian Journal of Infectious Diseases 2010;14(1):35-40.
37. Boisier P, Mahamane AE, Hamidou AA, Sidikou F, Djibo S, Nato F, et al. Field evaluation of rapid diagnostic tests for meningococcal meningitis in Niger. Tropical Medicine and International Health 2009;14:111-7.
38. Booy R, Habibi P, Nadel S, de Munter C, Britto Morrison JA, Levin M, et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Archives of Disease in Childhood 2001;85:386-90.
39. Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics 2009;123:e502-9. [DOI: 10.1542/peds.2008-0581]
40. Bourke TW, Fairley DJ, Shileds MD. Rapid diagnosis of meningococcal disease (editorial). Expert Review of Anti-infective Therapy 2010;8(12):1321-3.
41. Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. Journal of Infectious Diseases 1989;159(2):195-204.
42. Brandtzaeg P, van Deuren M. Meningococcal infections at the start of the 21st century. Advances in Pediatrics 2005;52:129-62.
43. The Campbell Collaboration. The Campbell Collaboration Economics Methods Policy Brief Version 1.0 April 2008. www.campbellcollaboration.org/artman2/uploads/1/Economic_Methods_Policy_Brief.pdf 2009 (accessed 21 July 2009).
44. Chanteau S, Rose AM, Djibo S, Nato F, Boisier P. Biological diagnosis of meningococcal meningitis in the African meningitis belt: current epidemic strategy and new perspectives. Vaccine 2007;25(Suppl 1):A30-6.
45. Duke T, Michael A, Mokela D, Wal T, Reeder J. Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries?. Archives of Disease in Childhood 2003;88(6):536-9.
46. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infectious Diseases 2010;10(5):317-28.
47. Eickhoff TC, Finland M. Changing susceptibility of meningococci to antimicrobial agents. New England Journal of Medicine 1965;272:395-8.
48. El Bashir H, Laundy M, Booy R. Diagnosis and treatment of bacterial meningitis. Archives of Disease in Childhood 2003;88:615-20.
49. Filali M, Noum M, Chakib A, Zahraoui M, Himmich H. Ceftriaxone versus penicillin G in the short term treatment of meningococcal meningitis in adults. European Journal of Clinical Microbiology & Infectious Diseases 1993;12:766-8.
50. Ferguson LE, Hormann MD. Neisseria meningitidis: presentation, treatment and prevention. Journal of Pediatric Health Care 2002;16:119-24.
51. Girgis N, Sultan Y, Frenck RW Jr, El-Gendy A, Farid Z, Mateczun A. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatric Infectious Disease Journal 1998;17:816-9.
52. GRADE Working Group, McMaster University. GRADEpro GDT [GRADEpro GDT]. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
53. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit P editor(s). Vaccines. 5th Edition. Philadelphia: Saunders Elsevier, 2008:399-434.
54. Hackett SJ, Guiver M, Marsh J, Sills JA, Thomson APJ, Kaczmarski EB, et al. Meningococcal bacterial DNA load at presentation correlates with disease severity. Archives of Disease in Childhood 2002;86:44-6.
55. Hahné SJM, Charlett A, Purcell B, Samuelsson S, Camaroni I, Ehrhard I, et al. Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ 2006;332:1299-303.
56. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
57. Higgins JP, Altman, DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
58. Higgins JP, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
59. Hill DJ, Griffiths NJ, Borodina E, Virji M. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clinical Science (London) 2010;9(118):547-64.
60. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. New England Journal of Medicine 2009;360(3):244-56.
61. Kanegaye JT, Soliemanzadeh P, Bradley JS. Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Pediatrics 2001;108:1169-74.
62. Keeley D. Parenteral penicillin before admission to hospital for meningitis. BMJ 2006;332:1283-4.
63. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
64. National Collaborating Centre for Women's and Children's Health. Feverish illness in children. Assessment and initial management in children younger than 5 years. NICE Clinical Guideline CG47. www.nice.org.uk/nicemedia/pdf/cg47niceguideline.pdf (accessed prior to 2 June 2017).
65. National Collaborating Centre for Women's and Children's Health. Bacterial meningitis and meningococcal septicaemia: the management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE Clinical Guideline CG 102. www.nice.org.uk/CG102 (accessed prior to 2 June 2017).
66. Pecoul B, Chirac P, Trouiller P, Pinel J, Pecoul B, Chirac P, et al. Access to essential drugs in poor countries: a lost battle?. JAMA 1999;281(4):361-7.
67. Perera R. Statistics and death from meningococcal disease in children. BMJ 2006;332(7553):1297-8.
68. Piaggio G, Elbourne D, Altman DG, Pocock SJ, Evans SJW, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. An extension of the CONSORT statement. JAMA 2006;295:1152-60.
69. Prasad K, Kumar A, Singhal T, Gupta PK. Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD001832.pub3]
70. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS. Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Medicine 2009;7:47. [DOI: 10.1186/1741-7015-7-47]
71. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
72. Rose AMC, Mueller JE, Gerstl S, Njanpop-Lafourcade B-M, Page A-L, Nicolas P, et al. Meningitis dipstick rapid test: evaluating diagnostic performance during an urban Neisseria meningitidis serogroup A outbreak, Burkina Faso, 2007. PLoS ONE 2010;5(6):e11086. [DOI: 10.1371/journal.pone.0011086]
73. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. New England Journal of Medicine 2001;344:1378-88.
74. Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods in Molecular Biology 2012;799:1-20.
75. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, et al. Functional significance of factor H binding to Neisseria meningitidis. Journal of Immunology 2006;176:7566-75.
76. Schubert-Unkmeir A, Konrad C, Slanina H, Czapek F, Hebling S, Frosch M. Neisseria meningitidis induces brain microvascular endothelial cell detachment from the matrix and cleavage of occludin: a role for MMP-8. PLoS Pathogens 2010;6(4):e1000874. [DOI: 10.1371/journal.ppat.1000874]
77. Schwartz B, Moore PS, Broome CV. Global epidemiology of meningococcal disease. Clinical Microbiology Reviews 1989;2(Suppl):118-24.
78. Scottish Intercollegiate Guidelines Network. Management of invasive meningococcal disease in children and young people. A National Clinical Guideline: 102. www.sign.ac.uk/pdf/sign102.pdf (accessed prior to 2 June 2017).
79. Sinclair D, Preziosi MP, John JT, Greenwood B. The epidemiology of meningococcal disease in India. Tropical Medicine and International Health 2010;15:1421-35.
80. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007;369:2196-201.
81. Tunkel AR, Scheld WM. Pathogenesis and pathophysiology of bacterial meningitis. Annual Reviews in Medicine 1993;44:103-20.
82. Wall ECB, Ajdukiewicz KMB, Heyderman RS, Garner P. Osmotic therapies added to antibiotics for acute bacterial meningitis. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD008806.pub2]
83. Wang VJ, Malley R, Fleisher GR, Inkelis SH, Kuppermann N. Antibiotic treatment of children with unsuspected meningococcal disease. Archives of Pediatrics and Adolescent Medicine 2000;154(6):556-60.
84. WHO Working Group. Control of Epidemic Meningococcal Diseases: WHO Practical Guidelines. Lyon, France: Edition Foundation Marcel Merieux, 1995.
85. World Health Organization. Meningococcal meningitis. www.who.int/csr/disease/meningococcal/en/ 2004 (accessed prior to 2 June 2017).
86. World Health Organization. Risk of epidemic meningitis in Africa: a cause for concern. Weekly Epidemiological Record 2007;82:77-88.
87. World Health Organization. Bacterial infections: meningococcal disease. www.who.int/vaccine_research/diseases/soa_bacterial/en/print.html 2010 (accessed prior to 2 June 2017).
88. Zalmanovici Trestioreanu A, Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD004785.pub5]
89. Sudarsanam T, Thomas K, Rupalli P, Abraham OC, Tharyan P. Pre-admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005437]
90. Sudarsanam T, Rupali P, Tharyan P, Abraham OC, Thomas K. Pre-admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD005437.pub2]
91. Sudarsanam T, Rupali P, Tharyan P, Abraham OC, Thomas K. Pre-admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD005437.pub2]
92. Sudarsanam T, Rupali P, Tharyan P, Abraham OC, Thomas K. Pre-admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD005437.pub3]